Turning aging cells into a live vaccine: engineered senescent cancer cells with adjuvant celecoxib for immunotherapy
Whole tumor cell (WTC) vaccines, characterized by their comprehensive antigenic profile, have the potential to minimize tumor immune evasion, but the limited immunogenicity and a rapid clearance of WTC vaccines often results in suboptimal therapeutic …